March 13 () - A trial directly comparing Eliquis and Xarelto - two commonly used blood-thinning drugs from the same class of medicines - found that Eliquis carries a clearly lower risk of dangerous ...

VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable ...

A trial directly comparing Eliquis and Xarelto - two commonly used blood-thinning drugs from ​the same class of medicines - found that Eliquis carries a clearly lower risk of dangerous bleeding in ...

There are a few main reasons why Clymer, Sherman and Panama school districts are the three looking into a potential merger, compared to joining up with any other schools in the local area, and this ...

Miller Career's C.J. Nelson (1) attempts a slam dunk during the fourth quarter of a Class 3 sectional boys basketball game at Fox High School in Arnold, Mo., on Tuesday, March 3, 2026. Miller Career ...

A large body of evidence demonstrates the use of technology in schools is nuanced, with more downsides to technology use than most people expect.

Thomas Smith Leerink Partners LLC, Research Division. Good morning, everyone. Thanks for joining us here at the Leerink Partners Global Healthcare Conference. My name is Tom Smith ...

I was like, ‘Is this real?’ because there is nothing like it,” lead author and clinical epidemiologist Ziyad Al-Aly said. “This is an obesity and diabetes drug; this is not an addiction ...

Peptilogics' PLG0206 is a first-in-class anti-biofilm drug candidate being studied in patients with prosthetic joint infection (PJI), the first of multiple potential medical device-related infections ...

REDWOOD CITY, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- CoherusOncology, Inc. (Nasdaq: CHRS), today reported financial results for the full year and fourth quarter 2025, and provided an overview of ...

AbbVie’s foray into the obesity space is successful so far, analysts agree, as amylin analog ABBV-295 elicited as much as 9.73% weight loss at 13 weeks in the multiple ascending dose portion of a ...